Alzheimer's Drug Discovery Foundation
- Research works
- 64 ▲ 44% vs 2013–17
- Citations
- 1.8k 27.4 per fractional work
- Top-10% rate
- 26.4% record average 16.5%
- Open access
- 60% world 28%
Not ranked overall: Alzheimer's Drug Discovery Foundation is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 8.6×. Every wedge is a field page.
- Economics, Econometrics and Finance 8.6×
- Neuroscience 3.5×
- Pharmacology, Toxicology and Pharmaceutics 2.7×
- Medicine 2.6×
- Health Professions 1.6×
- Business, Management and Accounting 1.2×
- Immunology and Microbiology 0.9×
- Psychology 0.9×
- Mathematics 0.8×
- Biochemistry, Genetics and Molecular Biology 0.8×
- Chemistry 0.7×
- Computer Science 0.6×
- Decision Sciences 0.3×
- Social Sciences 0.2×
- Environmental Science 0.0×
Who are the top researchers at Alzheimer's Drug Discovery Foundation?
Ranked on the composite score, Howard Fillit lead among researchers whose main affiliation is Alzheimer's Drug Discovery Foundation.
- 1 Howard Fillit United States · #199,710 worldwide 109 citations · 23 works
Which keywords describe research at Alzheimer's Drug Discovery Foundation?
By fractional works in all years, weighted toward what it does more of than the world: Alzheimer's Disease, Aging, Oxidative Stress, Biomarkers, Dementia, Quality of Life, Caregiver Burden and Neuroimaging.
- Long-Term Care
- Drug Development Costs
- Mitochondrial Dysfunction
- Multimorbidity
- Health Services
- Primary Care
- Molecular Docking
- Health Utility Measures
- Cholinesterase Inhibitors
- Machine Learning
- Pharmacokinetics
- Pharmacology
- Tau Pathology
- Neurodegenerative Diseases
- Neurodegeneration
- Cognitive Training
- Neuroimaging
- Quality of Life
- Biomarkers
- Aging
- Alzheimer's Disease
- Oxidative Stress
- Dementia
- Caregiver Burden
- Cognitive Decline
- Mild Cognitive Impairment
- Neuroinflammation
- Amyloid Hypothesis
- Inflammation
- Drug Development
- Toxicology
- Acetylcholinesterase
- Cost-effectiveness Analysis
- Medicinal Chemistry
- Virtual Screening
- Cognitive Impairment
- Chronic Conditions
- Elderly Patients
- Mortality Risk
- Generic Drugs
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Alzheimer's Disease14▲ 79×8 topics
- Aging11▲ 31×12 topics
- Oxidative Stress10▲ 8.7×15 topics
- Biomarkers9▲ 22×6 topics
- Dementia7▲ 157×2 topics
- Quality of Life7▲ 8.0×8 topics
- Caregiver Burden7▲ 131×2 topics
- Neuroimaging7▲ 38×3 topics
- Cognitive Decline7▲ 99×1 topic
- Cognitive Training7▲ 154×2 topics
- Mild Cognitive Impairment7▲ 171×1 topic
- Neurodegeneration6▲ 31×8 topics
- Neuroinflammation6▲ 34×4 topics
- Neurodegenerative Diseases6▲ 41×4 topics
- Amyloid Hypothesis5▲ 153×1 topic
- Tau Pathology5▲ 153×1 topic
- Inflammation5▲ 3.4×16 topics
- Pharmacology5▲ 22×2 topics
- Drug Development4▲ 49×2 topics
- Pharmacokinetics4▲ 25×3 topics
- Toxicology4▲ 33×3 topics
- Machine Learning4▲ 3.1×6 topics
- Acetylcholinesterase4▲ 232×1 topic
- Cholinesterase Inhibitors4▲ 232×1 topic
- Cost-effectiveness Analysis4▲ 85×1 topic
- Health Utility Measures4▲ 85×1 topic
- Medicinal Chemistry4▲ 17×2 topics
- Molecular Docking4▲ 44×1 topic
- Virtual Screening4▲ 88×1 topic
- Primary Care2▲ 9.2×3 topics
- Cognitive Impairment2▲ 15×6 topics
- Health Services2▲ 47×2 topics
- Chronic Conditions2▲ 59×1 topic
- Multimorbidity2▲ 102×1 topic
- Elderly Patients2▲ 24×2 topics
- Mitochondrial Dysfunction2▲ 7.8×5 topics
- Mortality Risk2▲ 13×2 topics
- Drug Development Costs2▲ 100×1 topic
- Generic Drugs2▲ 100×1 topic
- Long-Term Care2▲ 38×2 topics
Which research topics does Alzheimer's Drug Discovery Foundation publish most on?
By volume in 2022–2025: Health Systems, Economic Evaluations, Quality of Life, Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments and Cholinesterase and Neurodegenerative Diseases.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 2 works
- 2 Dementia and Cognitive Impairment Research Psychiatry and Mental health 2 works
- 3 Alzheimer's disease research and treatments Physiology 2 works
- 4 Cholinesterase and Neurodegenerative Diseases Pharmacology 1 works
- 5 Pharmaceutical Economics and Policy Economics and Econometrics 1 works
- 6 Computational Drug Discovery Methods Computational Theory and Mathematics 1 works
- 7 Innovation and Socioeconomic Development Business and International Management 0 works
- 8 Geriatric Care and Nursing Homes General Health Professions 0 works
- 9 Neurological Disease Mechanisms and Treatments Neurology 0 works
- 10 Neurological Disorders and Treatments Neurology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Alzheimer's Drug Discovery Foundation's research output changed?
Output in 2018–2022 was 44% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in New York
- Columbia University
- New York University
- Icahn School of Medicine at Mount Sinai
- Memorial Sloan Kettering Cancer Center
- City University of New York
- Human Growth Foundation
- Columbia University Irving Medical Center
- Rockefeller University
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.